First in Human Study: LIS1 an Induction Treatment in Kidney Transplanted Patients

  • participants needed
  • sponsor
    Xenothera SAS
Updated on 6 May 2021
Bernard Vanhove, Dr
Primary Contact
Institut klinick a experiment ln medic ny (3.2 mi away) Contact
body mass index
immunosuppressive agents
panel reactive antibody


This first in human study aims at evaluating LIS1, a stabilized solution of purified anti-T lymphocytes polyclonal glyco-humanized swine IgG with immunosuppressive activity, in regards of safety, T cell depletion, and pharmacokinetics / pharmacodynamics in 10 kidney transplant recipients.

Condition Renal transplant, Kidney Transplantation, kidney transplant, renal transplantation, kidney transplants
Treatment LIS1, LIS1
Clinical Study IdentifierNCT04431219
SponsorXenothera SAS
Last Modified on6 May 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note